244 related articles for article (PubMed ID: 2541654)
1. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.
Van t Wout JW; Mattie H; van Furth R
Antimicrob Agents Chemother; 1989 Feb; 33(2):147-51. PubMed ID: 2541654
[TBL] [Abstract][Full Text] [Related]
2. Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages.
Van 't Wout JW; Meynaar I; Linde I; Poell R; Mattie H; Van Furth R
J Antimicrob Chemother; 1990 May; 25(5):803-11. PubMed ID: 2165051
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole in neutropenic patients.
van't Wout JW
Chemotherapy; 1992; 38 Suppl 1():23-6. PubMed ID: 1319311
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.
Bannatyne RM; Cheng PC; Fong IW
Infection; 1992; 20(3):168-70. PubMed ID: 1644494
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Ghannoum MA; Okogbule-Wonodi I; Bhat N; Sanati H
J Chemother; 1999 Feb; 11(1):34-9. PubMed ID: 10078778
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.
Tsuchimori N; Hayashi R; Kitamoto N; Asai K; Kitazaki T; Iizawa Y; Itoh K; Okonogi K
Antimicrob Agents Chemother; 2002 May; 46(5):1388-93. PubMed ID: 11959573
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.
Khardori N; Nguyen H; Stephens LC; Kalvakuntla L; Rosenbaum B; Bodey GP
Antimicrob Agents Chemother; 1993 Apr; 37(4):729-36. PubMed ID: 8494367
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.
Troke PF; Andrews RJ; Brammer KW; Marriott MS; Richardson K
Antimicrob Agents Chemother; 1985 Dec; 28(6):815-8. PubMed ID: 3002246
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
Hata K; Kimura J; Miki H; Toyosawa T; Nakamura T; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2237-42. PubMed ID: 8891121
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of systemic mycoses in neutropenic patients using itraconazole. A comparative, randomized study with amphotericin B].
van't Wout JW; Novakova I; Verhagen CA; Fibbe WE; de Pauw BE; van der Meer JW
Med Klin (Munich); 1991 Dec; 86 Suppl 1():11-3. PubMed ID: 1663200
[TBL] [Abstract][Full Text] [Related]
11. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.
van Etten EW; van de Rhee NE; van Kampen KM; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1991 Nov; 35(11):2275-81. PubMed ID: 1804000
[TBL] [Abstract][Full Text] [Related]
12. SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
Karyotakis NC; Dignani MC; Anaissie EJ
Antimicrob Agents Chemother; 1995 Mar; 39(3):775-7. PubMed ID: 7793892
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of the triazole Bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis.
Pappagianis D; Zimmer BL; Theodoropoulos G; Plempel M; Hector RF
Antimicrob Agents Chemother; 1990 Jun; 34(6):1132-8. PubMed ID: 2393272
[TBL] [Abstract][Full Text] [Related]
14. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis.
Jafari HS; Sáez-Llorens X; Severien C; Parras F; Friedland I; Rinderknecht S; Ehrett S; Olsen KD; Abramowsky C; McCracken GH
Antimicrob Agents Chemother; 1994 Jan; 38(1):83-9. PubMed ID: 7511361
[TBL] [Abstract][Full Text] [Related]
15. Azole resistance in Candida albicans.
Smith KJ; Warnock DW; Kennedy CT; Johnson EM; Hopwood V; Van Cutsem J; Vanden Bossche H
J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models.
Sanati H; Ramos CF; Bayer AS; Ghannoum MA
Antimicrob Agents Chemother; 1997 Jun; 41(6):1345-8. PubMed ID: 9174196
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
[TBL] [Abstract][Full Text] [Related]
18. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B.
van't Wout JW; Novakova I; Verhagen CA; Fibbe WE; de Pauw BE; van der Meer JW
J Infect; 1991 Jan; 22(1):45-52. PubMed ID: 1848268
[TBL] [Abstract][Full Text] [Related]
20. The comparative efficacy of cilofungin, fluconazole and amphotericin B in disseminated Candida tropicalis infection in neutropenic mice.
Fong IW; Bannatyne RM; Cheng PC
Clin Invest Med; 1992 Oct; 15(5):434-9. PubMed ID: 1458716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
